Impaired Sars-Cov-2 Specific Antibody Responses in Patients Treated with Anti-CD20 Antibodies

It has been proposed that patients with hematologic malignancy and autoimmune diseases receiving anti-CD20 monoclonal antibody (mAb) therapy are particularly at risk of severe Coronavirus disease (COVID-19) because the profound and long-lasting B-cell depletion induced by anti-CD20 mAb may impair vi...

Descripción completa

Detalles Bibliográficos
Autores principales: Sottini, Alessandra, Imberti, Luisa, Paghera, Simone, Previcini, Vanessa, Cattaneo, Chiara, Quiros-Roldan, Eugenia, Capra, Ruggero, Rossi, Giuseppe, Dobbs, Kerry, Shaw, Elana, Notarangelo, Luigi D., Burbelo, Peter, Cohen, Jeffrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2020
Materias:
627.Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)-Results from Retrospective/Observational Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330377/
http://dx.doi.org/10.1182/blood-2020-141234

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330377/
http://dx.doi.org/10.1182/blood-2020-141234

Ejemplares similares